Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60,825 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.
Zang M, Hu X, Yuan G, Li R, Li W, Pang H, Li Q, Chen J. Zang M, et al. Among authors: li w, li q, li r. Int Immunopharmacol. 2023 Dec;125(Pt A):111019. doi: 10.1016/j.intimp.2023.111019. Epub 2023 Oct 24. Int Immunopharmacol. 2023. PMID: 37879230 Free article.
Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study.
Yuan G, Li W, Zang M, Li R, Li Q, Hu X, Zhang Q, Huang W, Ruan J, Pang H, Chen J. Yuan G, et al. Among authors: li w, li q, li r. Discov Oncol. 2024 Mar 9;15(1):68. doi: 10.1007/s12672-024-00917-1. Discov Oncol. 2024. PMID: 38460053 Free PMC article.
60,825 results
You have reached the last available page of results. Please see the User Guide for more information.